Pipeline
Opioid Overdose
| Product Candidate/Regulatory Pathway | Preclinical | Phase I | Phase II | Phase III | NDA | FDA Approval |
|---|---|---|---|---|---|---|
| NARCAN® Nasal Spray* | Approved | |||||
| OPNT003 Nalmefene Nasal Spray |
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
NDA
|
FDA Approval
|
Partnerships*
Alcohol Use Disorder
| Product Candidate/Regulatory Pathway | Preclinical | Phase I | Phase II | Phase III | NDA | FDA Approval |
|---|---|---|---|---|---|---|
| OPNT002 Opioid Antagonist Nasal Spray |
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
NDA
|
FDA Approval
|
Acute Cannabinoid Overdose
| Product Candidate/Regulatory Pathway | Preclinical | Phase I | Phase II | Phase III | NDA | FDA Approval |
|---|---|---|---|---|---|---|
| OPNT004 Drinabant (CB-1 Antagonist) |
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
NDA
|
FDA Approval
|
Partnerships
Opioid Use Disorder
| Product Candidate/Regulatory Pathway | Preclinical | Phase I | Phase II | Phase III | NDA | FDA Approval |
|---|---|---|---|---|---|---|
| OPNT005 Heroin Vaccine: hapten + liposome adjuvant* |
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
NDA
|
FDA Approval
|
| OPNT006 Opioid Antagonist Implant |
Preclinical
|
Phase I
|
Phase II
|
Phase III
|
NDA
|
FDA Approval
|
Partnerships*
